A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM) - PubMed
5 hours ago
- #cancer treatment
- #monoclonal antibodies
- #multiple myeloma
- Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) are key treatments for relapsed/refractory multiple myeloma (RRMM).
- The review covers mechanisms, efficacy, real-world effectiveness, and safety profiles of daratumumab, isatuximab, elotuzumab, and belantamab mafodotin in RRMM.
- Efficacy in patient subgroups, treatment sequencing challenges, and new antigen targets are discussed.
- The widespread use of daratumumab and isatuximab in first-line therapy is reshaping RRMM treatment.
- Ongoing research aims to optimize individualized treatment choices and sequencing of therapies, including mAbs, ADCs, CAR T-cell therapies, and bispecific antibodies.